Bevacizumab biosimilar - Innovent Biologics

Drug Profile

Bevacizumab biosimilar - Innovent Biologics

Alternative Names: IBI 305

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Lung cancer
  • Preclinical Colorectal cancer

Most Recent Events

  • 01 Nov 2016 Phase-III clinical trials in Lung cancer (Late-stage disease, Metastatic disease, Recurrent, Combination therapy, Treatment-naive) in China (Injection) (NCT02954172)
  • 01 Nov 2016 Innovent Biologics and WuXi CDS Clinical Research plan a phase III trial for Non-small cell lung cancer (Recurrent, Combination therapy, Treatment-naive, In adults, In the elderly) in China (NCT02954172)
  • 09 Jun 2015 Preclinical trials in Colorectal cancer in China (Injection) (Innovent Biologics pipeline, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top